Zydus Cadila Joins IO Therapy League With XOMA Tie-up
IL-2 Therapy Use So Far Limited By Toxicities
Executive Summary
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
You may also be interested in...
Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Mylan Reveals FDA Goal Date For Bevacizumab
Mylan and Biocon's global development alliance has so far led to two biosimilar launches in the US. A filing for a biosimilar of Genentech's Avastin (bevacizumab) submitted by Mylan may soon bring a third.
Pipeline Watch: Phase III Readouts In Fabry Disease, Uterine Fibroids
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.